Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
- Patient with ocular hypertension at least 22mg Hg
- Patient must be over 18 years old
- None listed in the protocol
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Efficacy and Tolerability of Xalatan in Patients | |||
| Official Title | Observational Study Assessing The Efficacy And Tolerability Of Xalatan? In Patients With Open Angle Glaucoma And /Or Ocular Hypertension. | |||
| Brief Summary | Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan. | |||
| Detailed Description |
| |||
| Study Type | Observational | |||
| Study Design | Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | adults with glauocma or ocular hypertension | |||
| Condition |
| |||
| Intervention | Drug: Xalatan 0.005% eye drops ophthalmic solution dosed once daily for 3 months Other Name: latanoprost | |||
| Study Groups/Cohorts | Study Drug - Xalatan 0.005% eye drops Intervention: Drug: Xalatan 0.005% eye drops | |||
| Publications * | Not Provided | |||
| * Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 1289 | |||
| Original Actual Enrollment | 1408 | |||
| Actual Study Completion Date | December 2007 | |||
| Actual Primary Completion Date | December 2007 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years to 65 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Egypt, Saudi Arabia, United Arab Emirates | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00950690 | |||
| Other Study ID Numbers | A6111128 A6111128 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2011 | |||
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
